February 2021 News
We published a preprint on the BioRΧiv server, observations on the biomarkers pNF-H and UCHL1 in the bodily fluids of patients recovering from a common type of thoracic surgery. This report “A study of the neuronal injury biomarkers pNF-H and UCHL1 in serum, CSF and urine in a cohort of thoracic endovascular aortic repair (TEVAR) patients”, by Beck et al., BioRΧiv 10.1101/2021.03.02.433405v1, in addition to documenting blood, CSF and urine levels of these two proteins in a large cohort of TEVAR patients, also provides important quantitative data on the levels of UCHL1 in healthy control blood samples using multiple antibodies, results with antibody data confirmed by mass spectroscopy. We also document the presence of UCHL1 in certain urine samples. We used novel pNF-H and UCHL1 assays developed for the MSD electrochemiluminescent platform using EnCor antibodies and ran all the several hundred assays in the EnCor lab. We also include epitope mapping and other data on our panel of UCHL1 antibodies including the widely used mouse monoclonal antibody MCA-BH7.
We have updated product data for our recombinant full length human proteins, NF-L, GFAP, Vimentin and UCHL1, products PROT-r-NF-L, PROT-r-GFAP, PROT-r-Vim and PROT-r-UCHL1 respectively. We now provide the exact amino acid sequence and composition, isoelectric point, molecular weight, extinction coefficient and other relevant data for each protein. These proteins are widely used as protein standard for ELISA, MSD, Luminex and Simoa type assays, and also as immunogens for antibody production. We will provide this information for all of our recombinant proteins shortly and have already done this for our full length recombinant rat GFAP protein PROT-r-GFAP-rat.
